HRQoL in Patients With Solid Tumors Treated With Hadrontherapy
Health Related Quality of Life (HRQoL) in Patients With Solid Tumors Treated With Hadrontherapy (HadroQoL).
CNAO National Center of Oncological Hadrontherapy
180 participants
Mar 27, 2023
OBSERVATIONAL
Conditions
Summary
The Quality of Life of patients treated with hadrontherapy is still limited. Two cohorts are established, they will be receiving specific standardized questionnaires to be evalutaed in their results.
Eligibility
Inclusion Criteria7
- Cohort A ("survivors"):
- Patients with at least a follow up of 5 years with head and neck, skull base and brain tumors and no evidence of progressive disease.
- The patient is able to give consent
- Histological and/or radiological diagnosis of head and neck tumors
- Patients candidate for curative intent hadrontherapy
- Patients ≥ 18 years of age
- The patient is able to give consent
Exclusion Criteria8
- Re-irradiation.
- Second tumor.
- Known cases of any psychiatric and neurological diseases leading to disability (eg, manic disorder, schizophrenia etc..), which could impair compilation of questionnaires or affect quality of life.
- Cohort B:
- Re-irradiation.
- Second tumor
- Known cases of any psychiatric and neurological diseases leading to disability (eg, manic disorder, schizophrenia etc..), which could impair compilation of questionnaires or affect quality of life
- Presence of diffused metastasis
Interventions
Enrolled people will be requested to fill in questionnaires. Cohort A affected by head and neck cancer: SF-12, EORTC QLQ-C30, EORTC QLQ-H\&N43, HADS, Brief COPE, BRCS. Cohort A affected by skull base/brain cancer: SF-12, EORTC QLQ-BN20, HADS, Brief COPE, BRCS. Cohort B will receive: EORTC QLQ-C30, BRCS, PROFFIT, SF-12, EORTC QLQ-H\&N43.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05947149